These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33893877)

  • 41. Pre-exposure prophylaxis for transgender women and men who have sex with men: qualitative insights from healthcare providers, community organization-based leadership and end users in coastal Kenya.
    Kimani M; Sanders EJ; Chirro O; Mukuria N; Mahmoud S; Rinke de Wit TF; Graham SM; Operario D; van der Elst EM
    Int Health; 2022 May; 14(3):288-294. PubMed ID: 34325469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
    PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
    Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya.
    Jackson-Gibson M; Ezema AU; Orero W; Were I; Ohiomoba RO; Mbullo PO; Hirschhorn LR
    BMC Public Health; 2021 Jul; 21(1):1284. PubMed ID: 34210288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique.
    Lahuerta M; Zerbe A; Baggaley R; Falcao J; Ahoua L; DiMattei P; Morales F; Ramiro I; El-Sadr WM
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):343-347. PubMed ID: 28777264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Provider perspectives on service delivery modifications to maintain access to HIV pre-exposure prophylaxis during the COVID-19 pandemic: qualitative results from a PrEP implementation project in Kenya.
    Velloza J; Roche SD; Owidi EJ; Irungu EM; Dollah A; Kwach B; Thuo NB; Morton JF; Mugo N; Bukusi EA; O'Malley G; Ngure K; Baeten JM; Mugwanya KK;
    J Int AIDS Soc; 2023 Feb; 26(2):e26055. PubMed ID: 36739603
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection.
    van Epps P; Maier M; Lund B; Howren MB; Beck B; Beste L; Skolnik A; Vaughan-Sarrazin M; Ohl ME
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):272-278. PubMed ID: 29210835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Providers' Attitudes and Experiences with Pre-Exposure Prophylaxis Implementation in a Population-Based Study in Kenya and Uganda.
    Camlin CS; Getahun M; Koss CA; Owino L; Akatukwasa C; Itiakorit H; Onyango A; Bakanoma R; Atwine F; Maeri I; Ayieko J; Atukunda M; Owaraganise A; Mwangwa F; Sang N; Kabami J; Kaplan RL; Chamie G; Petersen ML; Cohen CR; Bukusi EA; Kamya MR; Havlir DV; Charlebois ED
    AIDS Patient Care STDS; 2022 Oct; 36(10):396-404. PubMed ID: 36201226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling.
    Namey E; Agot K; Ahmed K; Odhiambo J; Skhosana J; Guest G; Corneli A
    Cult Health Sex; 2016 Sep; 18(9):1081-91. PubMed ID: 27093238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
    Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
    JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.
    Velloza J; Poovan N; Ndlovu N; Khoza N; Morton JF; Omony J; Mkwanazi E; Grabow C; Donnell D; Munthali R; Baeten JM; Hosek S; Celum C; Delany-Moretlwe S
    PLoS One; 2022; 17(4):e0266665. PubMed ID: 35417485
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
    Thomson KA; Baeten JM; Mugo NR; Bekker LG; Celum CL; Heffron R
    Curr Opin HIV AIDS; 2016 Jan; 11(1):18-26. PubMed ID: 26417954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Process evaluation of PrEP implementation in Kenya: adaptation of practices and contextual modifications in public HIV care clinics.
    Irungu EM; Odoyo J; Wamoni E; Bukusi EA; Mugo NR; Ngure K; Morton JF; Mugwanya KK; Baeten JM; O'Malley G;
    J Int AIDS Soc; 2021 Sep; 24(9):e25799. PubMed ID: 34496148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.